A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 Weeks for 2 Years, to Sham Injections in Subjects With Diabetic Macular Edema (DME) Involving the Center of the Macula With An Open-Label Macugen Year 3 Extension.
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Pegaptanib (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer
- 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00605280).
- 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00605280).
- 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00605280).